FDA-cleared profile

FETOLY-HEART

Diagnoly

Concurrent AI reading aid for routine fetal heart ultrasound examinations in second- and third-trimester pregnancies from 17 to 40 weeks, detecting the five recommended fetal heart views and 52 within-view quality criteria.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Concurrent AI reading aid for routine fetal heart ultrasound examinations in second- and third-trimester pregnancies from 17 to 40 weeks, detecting the five recommended fetal heart views and 52 within-view quality criteria.
FDA source Exact FDA submission Checked 2026-09-08
Intended users
Sonographers, obstetricians, radiologists, maternal-fetal medicine specialists, and pediatric cardiologists who are qualified healthcare professionals specialized in prenatal ultrasound imaging.
FDA source Exact FDA submission Checked 2026-09-08
Care setting and population
Routine fetal heart ultrasound examination during second- and third-trimester pregnancy, gestational age 17 to 40 weeks.
FDA source Exact FDA submission Checked 2026-09-08
Workflow role
Concurrent real-time acquisition and reading aid; displays examination completeness and an illustrative image subset while the healthcare professional acquires and interprets images, with clinician review, editing, or override.
FDA source Exact FDA submission Checked 2026-09-08
Required input
Real-time fetal ultrasound images and image sequences or clips from a connected ultrasound machine for second- and third-trimester examinations; the packet names GE Medical, Samsung, Canon, and Philips ultrasound compatibility in its comparison and testing materials.
FDA source Exact FDA submission Checked 2026-09-08
Output and human action
A real-time completeness overview identifying the abdomen, four-chamber, LVOT, RVOT, and three-vessel views and 52 quality criteria as verified or not verified, plus an illustrative image subset and optional quality-criterion localization boxes.
FDA source Exact FDA submission Checked 2026-09-08
Limitations
The device does not select the best or diagnostically highest-quality image; its illustration represents quantitative completeness, not diagnostic quality. Clinicians must verify the views and criteria. The FDA packet marks clinical performance data as not applicable and does not establish diagnostic use.
FDA source Exact FDA submission Checked 2026-09-08

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241380
FDA source Exact FDA submission Checked 2026-08-31
Modality
Ultrasound
FDA source Exact FDA submission Checked 2026-09-08
Anatomy
Obstetric fetal heart
FDA source Exact FDA submission Checked 2026-09-08
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2024-09-11
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Installed on hardware connected to the ultrasound machine through HDMI and receiving the ultrasound stream in real time; the FDA comparison describes local or edge operation independent of the ultrasound equipment and does not establish DICOM, PACS, RIS, or EHR interfaces.
FDA source Exact FDA submission Checked 2026-09-08
Deployment and data flow
Hybrid
Public source Exact FDA submission Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for FETOLY-HEART; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
FDA standalone performance testing used 2,288 fetal ultrasound images from 480 patient cases across 7 clinical sites in the United States and France, with test data distinct from model-development data. Acceptance criteria were sensitivity and specificity at least 85% for fetal heart views, sensitivity and specificity at least 90% for quality criteria within views, and mean bounding-box IoU at least 50% for quality-criteria localization. The packet describes paired annotators with adjudication as the reference process; clinical performance data are marked not applicable.
FDA source Exact FDA submission Checked 2026-09-08
Reported sensitivity
No single device-level value; fetal-heart-view point estimates range from 97.6% to 98.7%, with quality-criterion sensitivity reported per criterion.
FDA source Exact FDA submission Checked 2026-09-08

The 85% and 90% values are acceptance criteria and 50% is a localization IoU criterion, not an observed sensitivity or specificity result.

Reported specificity
No single device-level value; fetal-heart-view point estimates range from 98.3% to 100%, with quality-criterion specificity reported per criterion.
FDA source Exact FDA submission Checked 2026-09-08

The 85% and 90% values are acceptance criteria and 50% is a localization IoU criterion, not an observed sensitivity or specificity result.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FETOLY-HEART regulatory performance study summary

Stand-Alone Performance · Population described in the exact-submission ACR model card

exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K241380 · n=480 · 7 sites · Independence not established

K241380

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08

No public price or quote for the exact K241380 configuration was established in this review.

Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-08

No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241380. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Public source Exact FDA submission Checked 2026-09-08

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-08Last searched
23Fields reviewed
9Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-08.

Alternatives

Related tools to compare

FDA-cleared K251368

FETOLY

Diagnoly

FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements...

Modality
Ultrasound
Anatomy
Fetal heart and fetal brain
Decision
2025-09-12
FDA-cleared K251071

Fetal EchoScan (v1.1)

BrightHeart

Adjunctive detection of suspicious fetal cardiac findings during second-trimester ultrasound to aid concurrent OB-GYN or maternal-fetal-medicine interpretation.

Modality
Ultrasound
Anatomy
Fetal heart, including four-chamber, left-ventricular-outflow-tract, and right-ventricular-outflow-tract views and the specified suspicious cardiac findings
Decision
2025-05-02